eli lilly - Search News

Eli Lilly Cuts Sales Outlook

The Wall Street Journal on MSN · 16h

Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Investopedia on MSN · 5h

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

Reuters on MSN · 16h

Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.

Eli Lilly acquires cancer program from Scorpion Therapeutics

Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.

Business Insider · 1d

Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor

Hosted on MSN · 1d

Eli Lilly to buy cancer drug developer Scorpion Therapeutics for up to $2.5 billion

Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors.

Hosted on MSN16h

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty ...

14h

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

16h

6LLY : Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

8h

Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

14h

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results